Harmony Biosciences Holdings (HRMY) Total Current Liabilities (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Total Current Liabilities data on file, last reported at $217.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 24.11% year-over-year to $217.3 million; the trailing twelve-month figure through Mar 2026 stood at $217.3 million (up 24.11% YoY), and the FY2025 full-year result was $252.1 million, up 44.01% from the prior year.
• Total Current Liabilities fell to $217.3 million in Q1 2026, from $252.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $252.1 million in Q4 2025 to a low of $56.5 million in Q1 2022.
• A 5-year average of $144.0 million and a median of $154.3 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 125.43% in 2022 and climbed 4.7% in 2023, its largest moves.
• Tracing HRMY's Total Current Liabilities over 5 years: stood at $78.9 million in 2022, then soared by 107.62% to $163.8 million in 2023, then gained by 6.9% to $175.1 million in 2024, then soared by 44.01% to $252.1 million in 2025, then fell by 13.8% to $217.3 million in 2026.
• Business Quant data shows HRMY's Total Current Liabilities at $217.3 million in Q1 2026, $252.1 million in Q4 2025, and $223.4 million in Q3 2025.